| Affiliation: | 1. UMR 1253, iBRAIN, Université de Tours, INSERM , Tours, France;2. UMR 1253, iBRAIN, Université de Tours, INSERM , Tours, France;3. CHU De Tours, Service de Biochimie et Biologie Moléculaire , Tours, France;4. CHU de Tours, Service de Neurologie , Tours, France |
| Abstract: | ABSTRACT Introduction To date, riluzole and edaravone are the only two drugs that have successfully passed clinical trials for the treatment of Amyotrophic Lateral Sclerosis (ALS). Unfortunately, both drugs exhibit very modest effects. Most other drugs have failed at phase III to show significant effects in phase III when tested in larger cohorts. This pattern necessitates improvements in the approach to ALS pharmacotherapy. |
